Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 4/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 10/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.48 |
| ▸ | CASR | P41180 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | UBE2M | P61081 | 1/20 | 0.42 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4400506 | 0.89 | CASR (0.56) | CHRM3CASRSMN1; SMN2UBE2MDCUN1D1 | |
| SCHEMBL4396970 | 0.86 | KMT2A (0.48) | CHRM3ROCK2CASRSMN1; SMN2 | |
| SCHEMBL4391777 | 0.84 | CASR (0.53) | CASRSMN1; SMN2 | |
| SCHEMBL4393805 | 0.83 | CASR (0.62) | CASR | |
| SCHEMBL4393209 | 0.82 | SMN1; SMN2 (0.46) | CHRM3CASRSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4400765 | 0.82 | CASR (0.61) | CASR | |
| SCHEMBL4398678 | 0.80 | CHRM3 (0.44) | CHRM3 | |
| SCHEMBL4397067 | 0.80 | CASR (0.59) | CASR | |
| SCHEMBL4396965 | 0.80 | UBE2M (0.45) | CHRM3CASRSMN1; SMN2UBE2MDCUN1D1 | |
| SCHEMBL14472841 | 0.78 | CASR (0.43) | ROCK2CASRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605261-B2 | Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AMGEN INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | AVENTIS PHARMA S.A. (FR) | 2007-07-26 | — | — | US | disclosed |
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | PROSKELIA SAS (FR) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053925-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | HRH4, HRH2, RPS2 | CHRM3 79/4885ROCK2 2463/4885ROCK1 4163/4885 |
| US-20070173502-A1 | Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use | RPS2, NOX5, PRMT5 | CHRM3 182/4885ROCK2 4213/4885ROCK1 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.